Ivanisse Ortiz Velez
Internal Medicine · Dorado, PRNPI 1669953196
Payments from drug & device makers
Across 132 payments — averaging $38.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$829
- Boehringer Ingelheim$787
- GSK$511
- United Therapeutics Corporation$362
- Merck$317
- Sanofi$303
- plus $2K from 15 others
What the payments were for
- Food & beverage$4,87895%
- Education$2695%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $829 |
| Boehringer Ingelheim | 22 | $787 |
| GSK | 11 | $511 |
| United Therapeutics Corporation | 4 | $362 |
| Merck | 14 | $317 |
| Sanofi | 9 | $303 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $265 |
| Johnson & Johnson | 11 | $254 |
| Bayer | 2 | $249 |
| Actelion Pharmaceuticals US, Inc. | 2 | $212 |
| Sanofi-aventis U.S. LLC | 3 | $191 |
| Caris MPI, Inc. | 3 | $186 |
| Eli Lilly Export S.A. Puerto Rico Branch | 5 | $127 |
| PBG Puerto Rico LLC | 6 | $123 |
| Amgen | 4 | $108 |
| Mylan Specialty L.p. | 1 | $76 |
| Insmed, Inc. | 2 | $70 |
| AbbVie | 2 | $55 |
| E.r. Squibb & Sons, L.L.C. | 2 | $52 |
| Jazz Pharmaceuticals Inc. | 2 | $50 |
| Viatris Specialty LLC | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,147 in reported general payments places this provider in the 90th percentile of 1,043 internal medicine providers in Puerto Rico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 14 | $181,691 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,969 |
| EliquisApixaban | 13 | $7,868 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $660 |
| Nifedipine ErNifedipine | 17 | $460 |
| Fluticasone Propionate | 16 | $260 |
| Atorvastatin Calcium | 26 | $250 |
| Montelukast Sodium | 23 | $172 |
| Losartan Potassium | 14 | $147 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $787 | $181,69114 claims |
| GSKTrelegy Ellipta | $511 | $7,96912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,043 internal medicine providers in Puerto Rico.
Other internal medicine in Dorado
- Angel VinuelaDorado$182K
- Elizabeth BarrancoPonce$8M
- Grisell Ortiz LasantaSan Juan$5.9M
- Ruben Santiago-LugoGuaynabo$1.3M
- Nelson VallejoLas Piedras$621K
- Ricardo FernandezSan Juan$480K
- Ronald Collazo PaganManati$206K
- Evelyn Matta FontanetRio Grande$200K
- Lumen Vera ColonAibonito$179K
- Pedro del Valle de TomasSan Juan$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.